Skip to content

EPS (Basic) at other companies

Amgen logo
AmgenAMGN
$3.37+4.7%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
-$0.79-141%
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
-$0.79-17.9%
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
-$0.42+38.2%
Fortrea Holdings Inc. logo
Fortrea Holdings Inc.FTRE
-$0.25+96.0%
Precigen logo
PrecigenPGEN
-$0.02+88.9%

Other financials

Income statement

See full
Revenue$26.5M+12,011%
Operating income-$13.3M+48.7%
Net income-$8.6M+59.8%
EPS (diluted)-$0.19+61.2%

Balance sheet

See full
Cash & equivalents$71.6M-65.9%
Total debt$23.1M-7.7%
Total equity$378.5M+195%
Total assets$569.7M+31.3%

Cash flow

See full
Operating cash flow-$25.6M-9.8%
CapEx$832.0K+118%
Free cash flow-$26.5M-11.5%

Valuation

See full
Market cap$1.62B+319%

Profitability

See full
Operating margin-77.1%-38.4pp
Net margin-49.9%-24.9pp
FCF margin467.9%+243pp

Returns & leverage

See full
Return on equity-12.2%
Debt / equity0.1×
Current ratio4.7×-27.5×

Where this comes from

Reported directly by Septerna, Inc. in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.

The official record: Septerna, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Septerna, Inc.'s eps (basic).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Septerna, Inc.'s EPS (basic)?
Septerna, Inc. (SEPN) reported EPS (basic) of -$0.19 in Q1 2026.
How has Septerna, Inc.'s EPS (basic) changed year-over-year?
Septerna, Inc.'s EPS (basic) increased by 61.2% year-over-year, from -$0.49 to -$0.19.
What does EPS (basic) mean?
Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.